Moderna (MRNA) Competitors $27.60 -1.96 (-6.63%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$27.72 +0.13 (+0.45%) As of 08/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MRNA vs. CRSP, CVAC, HOOD, NVAX, OCGN, TSLA, JNJ, MRK, PFE, and TAKShould you be buying Moderna stock or one of its competitors? The main competitors of Moderna include CRISPR Therapeutics (CRSP), CureVac (CVAC), Robinhood Markets (HOOD), Novavax (NVAX), Ocugen (OCGN), Tesla (TSLA), Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), and Takeda Pharmaceutical (TAK). Moderna vs. Its Competitors CRISPR Therapeutics CureVac Robinhood Markets Novavax Ocugen Tesla Johnson & Johnson Merck & Co., Inc. Pfizer Takeda Pharmaceutical CRISPR Therapeutics (NASDAQ:CRSP) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, media sentiment, profitability, risk, institutional ownership and analyst recommendations. Is CRSP or MRNA more profitable? Moderna has a net margin of -105.67% compared to CRISPR Therapeutics' net margin of -1,023.64%. CRISPR Therapeutics' return on equity of -20.08% beat Moderna's return on equity.Company Net Margins Return on Equity Return on Assets CRISPR Therapeutics-1,023.64% -20.08% -17.13% Moderna -105.67%-28.69%-21.94% Which has preferable valuation and earnings, CRSP or MRNA? CRISPR Therapeutics has higher earnings, but lower revenue than Moderna. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCRISPR Therapeutics$37.31M129.83-$366.25M-$4.52-12.41Moderna$3.24B3.30-$3.56B-$8.73-3.16 Does the media prefer CRSP or MRNA? In the previous week, Moderna had 24 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 39 mentions for Moderna and 15 mentions for CRISPR Therapeutics. Moderna's average media sentiment score of 0.36 beat CRISPR Therapeutics' score of 0.33 indicating that Moderna is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CRISPR Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Moderna 8 Very Positive mention(s) 1 Positive mention(s) 12 Neutral mention(s) 15 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer CRSP or MRNA? CRISPR Therapeutics presently has a consensus price target of $71.31, suggesting a potential upside of 27.14%. Moderna has a consensus price target of $46.11, suggesting a potential upside of 67.07%. Given Moderna's higher possible upside, analysts plainly believe Moderna is more favorable than CRISPR Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CRISPR Therapeutics 1 Sell rating(s) 6 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.53Moderna 4 Sell rating(s) 17 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.04 Do insiders & institutionals hold more shares of CRSP or MRNA? 69.2% of CRISPR Therapeutics shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 4.3% of CRISPR Therapeutics shares are owned by company insiders. Comparatively, 11.0% of Moderna shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has more volatility & risk, CRSP or MRNA? CRISPR Therapeutics has a beta of 1.8, indicating that its share price is 80% more volatile than the S&P 500. Comparatively, Moderna has a beta of 1.83, indicating that its share price is 83% more volatile than the S&P 500. SummaryModerna beats CRISPR Therapeutics on 10 of the 17 factors compared between the two stocks. Get Moderna News Delivered to You Automatically Sign up to receive the latest news and ratings for MRNA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MRNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MRNA vs. The Competition Export to ExcelMetricModernaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.43B$3.00B$5.47B$9.53BDividend YieldN/A2.44%4.74%4.08%P/E Ratio-3.1617.6228.6723.80Price / Sales3.30269.12422.3188.12Price / CashN/A41.9535.4557.96Price / Book0.978.508.275.55Net Income-$3.56B-$55.06M$3.24B$259.03M7 Day Performance-19.18%-3.98%-3.63%-4.56%1 Month Performance-8.85%9.59%4.40%4.49%1 Year Performance-68.12%6.72%25.97%18.05% Moderna Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MRNAModerna4.4648 of 5 stars$27.60-6.6%$46.11+67.1%-70.7%$11.43B$3.24B-3.165,800Trending NewsEarnings ReportAnalyst ForecastOptions VolumeGap DownCRSPCRISPR Therapeutics3.5139 of 5 stars$64.40-0.6%$71.31+10.7%+2.3%$5.55B$35M-14.23460Upcoming EarningsAnalyst RevisionGap DownCVACCureVac3.578 of 5 stars$5.45-0.3%$6.83+25.5%+51.1%$1.22B$579.18M5.92880HOODRobinhood Markets3.3657 of 5 stars$106.33+1.4%$85.29-19.8%+393.6%$94.22B$2.95B60.462,300Trending NewsEarnings ReportAnalyst ForecastInsider TradeGap DownNVAXNovavax4.5885 of 5 stars$7.31-2.2%$15.86+117.1%-47.8%$1.18B$682.16M2.761,990News CoverageUpcoming EarningsGap DownOCGNOcugen1.465 of 5 stars$1.06-3.2%$6.00+468.7%-23.6%$308.09M$4.05M-5.5580News CoverageGap DownTSLATesla4.2544 of 5 stars$327.19+3.5%$302.75-7.5%+39.6%$1.06T$97.69B189.87125,665Trending NewsAnalyst ForecastShort Interest ↑JNJJohnson & Johnson4.6667 of 5 stars$166.88-0.8%$174.50+4.6%+4.1%$401.92B$88.82B17.87138,100Trending NewsAnalyst RevisionMRKMerck & Co., Inc.4.997 of 5 stars$84.84+0.1%$108.69+28.1%-30.4%$212.96B$63.92B12.3575,000Positive NewsEarnings ReportAnalyst ForecastOptions VolumeAnalyst RevisionPFEPfizer4.9525 of 5 stars$24.56-0.9%$28.55+16.3%-23.4%$139.60B$63.63B17.7981,000Trending NewsUpcoming EarningsTAKTakeda Pharmaceutical2.3897 of 5 stars$14.35-0.9%N/A+2.3%$45.61B$30.09B65.1647,455Gap Up Related Companies and Tools Related Companies CRISPR Therapeutics Alternatives CureVac Alternatives Robinhood Markets Alternatives Novavax Alternatives Ocugen Alternatives Tesla Alternatives Johnson & Johnson Alternatives Merck & Co., Inc. Alternatives Pfizer Alternatives Takeda Pharmaceutical Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MRNA) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Moderna, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Moderna With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
